• Colorectal Cancer Info MAIN MENU
  • Screen MAIN MENU
  • Care MAIN MENU
  • Cure MAIN MENU
  • Get Involved MAIN MENU
  • Our Mission MAIN MENU

Subscribe to the Newsletter

What is the UGT1A1 biomarker?


The UGT1A1 gene is present in each of the cells in our body. The UGT1A1 gene provides instructions for making a protein called UDP glucuronosyltransferases. This normal (wild type) protein is an enzyme that is most active in the liver. The enzyme converts toxic molecules (by-products of drugs) into non-toxic molecules so that they can be removed from the body.

Irinotecan is a chemotherapy drug commonly used to treat colorectal cancer, either alone or in a combination with FOLFIRI. Irinotecan is converted in the body to a very toxic molecule that kills cancer cells. But, if the active and toxic molecule is not removed from the body fast enough, it will also attack normal healthy cells and destroy the liver and other tissues. Patients with a UGT1A1 mutation cannot convert Irinotecan’s active and toxic ingredient to non-toxic. This can lead to severe toxicity (especially liver toxicity). The most common and studied mutation, UGT1A1*28, is only 30% active compared to the normal enzyme.

What does UGT1A1 mutation mean?


When is it appropriate to test this biomarker?


Testing for UGT1A1 mutations is not required. Patients usually get tested after experiencing severe toxicity during treatment with FOLFIRI, or FOLFIRINOX or Irinotecan alone. The FDA-approved drug labels include warnings about toxicity.

What do I do with this information?


Every treatment has the potential to cause some side effects. Some people may be more sensitive to a drug than others. If you are experiencing severe side effects during treatment with irinotecan, FOLFIRI, or FOLFIRINOX), call your doctor immediately. You should discuss pharmacogenetic testing with your doctor. Results may show if you have a UGT1A1 gene mutation that puts you at risk for experiencing severe toxicity or side effects.

The Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommend dose reduction based on the type of UGT1A1 mutation or enzyme activity. Some patients may have mutations in both DPYD and UGT1A1. If you have mutations in both genes, you and your doctor can decide the best treatment plan that will be effective and safe for you.

What are the potential side effects?


Every treatment has the potential to cause some side effects. Some people may be more sensitive than others to a particular drug. It also depends on your other treatments, medications, vitamins and herbal supplements. For example, side effects could be worse if you are treated with radiation at the same time. Your cancer drugs may also interact with vitamins and herbal supplements, which means it is dangerous to take them together. Tell your doctor and pharmacist about all of your medications, vitamins, and treatments. Call your doctor immediately if you are experiencing severe symptoms.

For more on side effects of other chemotherapy regimens, click here.


Download: UGT1A1 Biomarker

Learn about the UGT1A1 Biomarker.

Download English

Latest Updates

Upcoming Events

Are you sure?

Clicking "Start Over" will empty your resources drawer and take you back to the beginning of the journey customizer. Would you like to continue?

Are you sure?

Clicking "Exit" will permanently close your resource drawer for the rest of the session. If you would like to minimize the drawer and access it from other pages, click the symbol next to "MY RESOURCES". Would you like to permanently exit the drawer?